RBR-2tz9dky招募中2 期
A phase 2, randomized, double blind, placebo-controlled multicentre study to evaluate the safety and tolerability of Pentosan Polysulfate Sodium in treating subjects with Mucopolysaccharidosis (MPS) type VI (Maroteaux-Lamy Syndrome)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 5Y 至 0（—）
入选标准
- •Male and female subjects greater than or equal to 5 years of age; Confirmed diagnosis by genetic testing and/or enzyme activity of MPS type VI (N-acetylgalactosamine-4-sulfatase deficiency and a second normal sulfatase enzyme); Must be on enzyme replacement therapy (ERT) for greater than or equal to 1 year; Must be on at stable dose of ERT for 3 months prior to baseline; Must have a mean pain score of a minimum of 3 and a maximum of 9 on the Faces Pain Scale – Revised (FPS-R) taken from the first 5 consecutive measurements at screening; Able to walk 30 metres with or without use of an assistive device; 6MWT less than or equal to 70% predicted of normative mean value for age; Subject demonstrates an impairment of ROM in at least one shoulder; Subject or parent, or legally acceptable representative sufficiently able to understand the purposes and risks of the study and able to provide written informed consent or in the case of subjects age less then 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures or study assessment; If applicable, subjects must be willing to comply with the medically acceptable contraceptive requirements of the study from screening to at least 28 days after the last investigational product (IP) administration. Subjects should not be pregnant or breastfeeding at the time of study entry; Subjects must be willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Documented or reported history of increased bleeding tendency in the presence or absence of anticoagulant or antiplatelet drugs; History of heparin induced thrombocytopenia; Current treatment with anticoagulants or antiplatelet drugs, excluding aspirin less than or equal to 100 mg per day; Absence of limitation in upper extremity fine motor skills; Absence of shoulder joint ROM limitations; Subject taking opioids within 2 weeks of Day 1 or unwilling to stop the treatment opioids throughout the study; Parenteral iloprost from 12 weeks before Day 1 and throughout the study; Parenteral bisphosphonates from 12 months before Day 1 and throughout the study; Currently active or recent history (within preceding 12 months) of a gastric or duodenal ulcer, or suspicion of gastrointestinal (GI) tract bleeding; Coagulation parameters or platelets outside laboratory reference range, liver function tests greater than or equal to 1.5 × upper limit of normal (ULN), or estimated glomerular filtration rate (eGFR) less then 30 mL per min at Screening; Hepatic synthetic insufficiency (including Gilbert’s Syndrome); History of bone marrow transplant or haematopoietic stem cell transplant; History or evidence of chondrocalcinosis or fibromyalgia; History or evidence of HIV, hepatitis B or hepatitis C; Major surgery within 12 weeks preceding Day 1 or anticipated surgery in the study period; Medical history or evidence of any clinically significant active or chronic condition involving the musculoskeletal system, which in the opinion of the Investigator may impact assessment of safety or efficacy parameters or the validity of study results; Current or recent immunosuppressive or immunomodulatory systemic therapy; Currently hospitalised; Any acute illness within 2 weeks of baseline; A history of drug or alcohol abuse and/or dependence as documented by subject/caregiver reporting within the 12 months preceding screening; Participation in another clinical trial or administration of any IP or experimental product within 12 weeks or five half-lives (whichever is longer) preceding Day 1; History of significant hypersensitivity to PPS or drugs of a similar chemical or pharmacological class; Any clinically significant abnormalities as judged by the Investigator at screening; History of or current clinically significant GI, hepatic, renal, cardiovascular, respiratory, endocrine, oncological, immunological, neurological, ophthalmological (including existing pigmentary maculopathy), haematological or psychiatric disorder or any other condition (with the exception of signs and symptoms relating to MPS VI), which in the opinion of the Investigator or Sponsor would jeopardize the safety of the subject or the validity of the study results; An employee of the Sponsor or research site personnel directly affiliated with this study or their immediate family members defined as a spouse, parent, sibling, or child, whether biological or legally adopted;
研究者
相似试验
进行中（未招募）
1 期
A phase 2 multi-centre study to evaluate the efficacy and safety of a chemokine CCR2/5 receptor antagonist in adults with type 2 diabetes and overt nephropathy.MedDRA version: 15.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersDiabetic nephropathyEUCTR2012-003332-23-ESPfizer Inc., 235 42nd Street, New York, NY 10017, USA226
进行中（未招募）
1 期
A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in subjects with distal subungual onychomycosis.Distal subungual onychomycosisMedDRA version: 8.1Level: PTClassification code 10030338Term: OnychomycosisMedDRA version: 9.1Level: LLTClassification code 10030338Term: OnychomycosisEUCTR2008-002418-23-ISStiefel Laboratories Inc.550
未知
2 期
A phase 2, randomized, double-blind, placebo-controlled, add-on study of DS-8500a in Japanese patients with type 2 diabetes mellitus receiving sitagliptiType 2 Diabetes MellitusJPRN-jRCT2080223082DAIICHI SANKYO CO., LTD.90
进行中（未招募）
不适用
A phase 2 multi-centre study to evaluate the efficacy and safety of a chemokine CCR2/5 receptor antagonist in adults with type 2 diabetes and overt nephropathy.Diabetic nephropathyEUCTR2012-003332-23-ITPfizer Inc., 235 42nd Street, New York, NY 10017, USA176
进行中（未招募）
不适用
A phase 2 multi-centre study to evaluate the efficacy and safety of a chemokine CCR2/5 receptor antagonist in adults with type 2 diabetes and overt nephropathy.Diabetic nephropathyEUCTR2012-003332-23-PLPfizer Inc., 235 42nd Street, New York, NY 10017, USA176